Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, Division of Hematology & Medical Oncology, 2220 Pierce Avenue, Nashville, TN 37232, USA.
Expert Opin Ther Targets. 2009 Jun;13(6):675-88. doi: 10.1517/14728220902915567. Epub 2009 May 2.
Multiple lines of evidence suggest that cyclooxygenase-2 (COX-2) upregulation is an early event in the development of non-small-cell lung cancer. Preclinical data indicate tumors with upregulation of COX-2 synthesize high levels of prostaglandin E₂ (PGE₂), which in turn are associated with increased production of proangiogenic factors and enhanced metastatic potential. These findings indicate that an increase in COX-2 expression may play a significant role in the development and growth of lung cancers and possibly with the acquisition of an invasive and metastatic phenotype. Consequently, inhibitors of COX-2 are being studied for their chemopreventative and therapeutic effects in individuals at high risk for lung cancer and patients with established cancers.
有多项证据表明，环氧化酶-2（COX-2）的上调是非小细胞肺癌发展过程中的早期事件。临床前数据表明，COX-2 上调的肿瘤合成高水平的前列腺素 E₂（PGE₂），这反过来又与促血管生成因子的产生增加和转移潜能增强有关。这些发现表明，COX-2 表达的增加可能在肺癌的发展和生长中起重要作用，并且可能与获得侵袭性和转移性表型有关。因此，COX-2 抑制剂正在高危人群和已确诊癌症患者中进行化学预防和治疗作用的研究。
